SCHEMBL6795524

SCHEMBL6795524

COc1ccc(C2=NC(=Cc3ccccc3)C(=O)O2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
KDM4E B2RXH2 2/20 0.67
MAPT P10636 1/20 0.67
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
TNNI3 P19429 1/20 0.64
CRHBP P24387 1/20 0.64
TNNT2 P45379 1/20 0.64
TNNC1 P63316 1/20 0.64
CRHR2 Q13324 1/20 0.64
NOTUM Q6P988 1/20 0.64
CSNK2A2 P19784 3/20 0.59
CSNK2B P67870 3/20 0.59
CSNK2A1 P68400 3/20 0.59
DAPK3 O43293 3/20 0.58
PLCG2 P16885 1/20 0.56
GAA P10253 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ALOX5 P09917 2/20 0.54
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795520 1.00 ALDH1A1 (0.67) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL6796548 0.94 MEN1 (0.67) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL6796550 0.94 MEN1 (0.67) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL15421524 0.94 MEN1 (0.67) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL1241572 0.94 ALDH1A1 (0.62) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL29518211 0.87 CSNK2A2 (0.78) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL22505155 0.87 CSNK2A2 (0.78) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL6799713 0.85 POLB (0.71) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL6799710 0.85 POLB (0.71) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL2131623 0.85 DAPK3 (0.75) ALDH1A1KDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 ALDH1A1 905/4885KDM4E 4805/4885MAPT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.